Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1997 Feb;62(2):133–140. doi: 10.1136/jnnp.62.2.133

[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.

J Booij 1, G Tissingh 1, G J Boer 1, J D Speelman 1, J C Stoof 1, A G Janssen 1, E C Wolters 1, E A van Royen 1
PMCID: PMC486723  PMID: 9048712

Abstract

OBJECTIVES: The main neuropathological feature in Parkinson's disease is a severe degeneration of the dopaminergic neurons in the substantia nigra resulting in a loss of dopamine (DA) transporters in the striatum. [123I]beta-CIT single photon emission computed tomography (SPECT) studies have demonstrated this loss of striatal DA transporter content in Parkinson's disease in vivo. However, studies with this radioligand also showed that an adequate imaging of the striatal DA transporter content could only be performed on the day after the injection of radioligand, which is not convenient for outpatient evaluations. Recently, a new radioligand [123I]FP-CIT, with faster kinetics than beta-CIT, became available for imaging of the DA transporter with SPECT, and the applicability of this ligand was tested in patients with early and advanced Parkinson's disease, using a one day protocol. METHODS: [123I]FP-CIT SPECT was performed in six patients with early and 12 patients with advanced Parkinson's disease, and in six age matched healthy volunteers. RESULTS: Compared with an age matched control group striatal [123I]FP-CIT uptake in patients with Parkinson's disease was decreased, and this result was measurable three hours after injection of the radioligand. In the Parkinson's disease group the uptake in the putamen was reduced more than in the caudate nucleus. The contralateral striatal uptake of [123I]FP-CIT was significantly lower than the ipsilateral striatal uptake in the Parkinson's disease group. Specific to non-specific striatal uptake ratios correlated with the Hoehn and Yahr stage. A subgroup of patients with early Parkinson's disease also showed significantly lower uptake in the putamen and lower putamen:caudate ratios than controls. CONCLUSION: [123I]FP-CIT SPECT allows a significant discrimination between patients with Parkinson's disease and age matched controls with a one day protocol, which will be to great advantage in outpatient evaluations.

Full text

PDF
133

Images in this article

135Image
on p.135
140Image
on p.140

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abi-Dargham A., Gandelman M. S., DeErausquin G. A., Zea-Ponce Y., Zoghbi S. S., Baldwin R. M., Laruelle M., Charney D. S., Hoffer P. B., Neumeyer J. L. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med. 1996 Jul;37(7):1129–1133. [PubMed] [Google Scholar]
  2. Allard P., Marcusson J. O. Age-correlated loss of dopamine uptake sites labeled with [3H]GBR-12935 in human putamen. Neurobiol Aging. 1989 Nov-Dec;10(6):661–664. doi: 10.1016/0197-4580(89)90001-8. [DOI] [PubMed] [Google Scholar]
  3. Baldwin R. M., Zea-Ponce Y., al-Tikriti M. S., Zoghbi S. S., Seibyl J. P., Charney D. S., Hoffer P. B., Wang S., Milius R. A., Neumeyer J. L. Regional brain uptake and pharmacokinetics of [123I]N-omega-fluoroalkyl-2 beta-carboxy-3 beta-(4-iodophenyl)nortropane esters in baboons. Nucl Med Biol. 1995 Feb;22(2):211–219. doi: 10.1016/0969-8051(94)00096-3. [DOI] [PubMed] [Google Scholar]
  4. Bergström K. A., Halldin C., Kuikka J. T., Swahn C. G., Tiihonen J., Hiltunen J., Länsimies E., Farde L. Lipophilic metabolite of [123I]beta-CIT in human plasma may obstruct quantitation of the dopamine transporter. Synapse. 1995 Apr;19(4):297–300. doi: 10.1002/syn.890190407. [DOI] [PubMed] [Google Scholar]
  5. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973 Dec;20(4):415–455. doi: 10.1016/0022-510x(73)90175-5. [DOI] [PubMed] [Google Scholar]
  6. Brooks D. J. Functional imaging in relation to parkinsonian syndromes. J Neurol Sci. 1993 Mar;115(1):1–17. doi: 10.1016/0022-510x(93)90061-3. [DOI] [PubMed] [Google Scholar]
  7. Brooks D. J., Ibanez V., Sawle G. V., Quinn N., Lees A. J., Mathias C. J., Bannister R., Marsden C. D., Frackowiak R. S. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol. 1990 Oct;28(4):547–555. doi: 10.1002/ana.410280412. [DOI] [PubMed] [Google Scholar]
  8. Brücke T., Kornhuber J., Angelberger P., Asenbaum S., Frassine H., Podreka I. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT. Binding kinetics in the human brain. J Neural Transm Gen Sect. 1993;94(2):137–146. doi: 10.1007/BF01245007. [DOI] [PubMed] [Google Scholar]
  9. De Keyser J., De Backer J. P., Ebinger G., Vauquelin G. [3H]GBR 12935 binding to dopamine uptake sites in the human brain. J Neurochem. 1989 Nov;53(5):1400–1404. doi: 10.1111/j.1471-4159.1989.tb08530.x. [DOI] [PubMed] [Google Scholar]
  10. Farde L., von Bahr C. Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET. Acta Psychiatr Scand Suppl. 1990;358:67–71. doi: 10.1111/j.1600-0447.1990.tb05292.x. [DOI] [PubMed] [Google Scholar]
  11. Frost J. J., Rosier A. J., Reich S. G., Smith J. S., Ehlers M. D., Snyder S. H., Ravert H. T., Dannals R. F. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol. 1993 Sep;34(3):423–431. doi: 10.1002/ana.410340331. [DOI] [PubMed] [Google Scholar]
  12. Gibb W. R., Lees A. J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745–752. doi: 10.1136/jnnp.51.6.745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Goto S., Hirano A., Matsumoto S. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration. Ann Neurol. 1989 Dec;26(6):766–770. doi: 10.1002/ana.410260613. [DOI] [PubMed] [Google Scholar]
  14. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  15. Hornykiewicz O., Kish S. J. Biochemical pathophysiology of Parkinson's disease. Adv Neurol. 1987;45:19–34. [PubMed] [Google Scholar]
  16. Innis R. B., Seibyl J. P., Scanley B. E., Laruelle M., Abi-Dargham A., Wallace E., Baldwin R. M., Zea-Ponce Y., Zoghbi S., Wang S. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11965–11969. doi: 10.1073/pnas.90.24.11965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kaufman M. J., Madras B. K. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse. 1991 Sep;9(1):43–49. doi: 10.1002/syn.890090107. [DOI] [PubMed] [Google Scholar]
  18. Kilbourn M. R., Sherman P. S., Pisani T. Repeated reserpine administration reduces in vivo [18F]GBR 13119 binding to the dopamine uptake site. Eur J Pharmacol. 1992 May 27;216(1):109–112. doi: 10.1016/0014-2999(92)90216-q. [DOI] [PubMed] [Google Scholar]
  19. Kish S. J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med. 1988 Apr 7;318(14):876–880. doi: 10.1056/NEJM198804073181402. [DOI] [PubMed] [Google Scholar]
  20. Kuikka J. T., Bergström K. A., Ahonen A., Hiltunen J., Haukka J., Länsimies E., Wang S., Neumeyer J. L. Comparison of iodine-123 labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med. 1995 Apr;22(4):356–360. doi: 10.1007/BF00941854. [DOI] [PubMed] [Google Scholar]
  21. Langston J. W., Widner H., Goetz C. G., Brooks D., Fahn S., Freeman T., Watts R. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord. 1992;7(1):2–13. doi: 10.1002/mds.870070103. [DOI] [PubMed] [Google Scholar]
  22. Laruelle M., Baldwin R. M., Malison R. T., Zea-Ponce Y., Zoghbi S. S., al-Tikriti M. S., Sybirska E. H., Zimmermann R. C., Wisniewski G., Neumeyer J. L. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse. 1993 Apr;13(4):295–309. doi: 10.1002/syn.890130402. [DOI] [PubMed] [Google Scholar]
  23. Laruelle M., Wallace E., Seibyl J. P., Baldwin R. M., Zea-Ponce Y., Zoghbi S. S., Neumeyer J. L., Charney D. S., Hoffer P. B., Innis R. B. Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab. 1994 Nov;14(6):982–994. doi: 10.1038/jcbfm.1994.131. [DOI] [PubMed] [Google Scholar]
  24. Leenders K. L., Salmon E. P., Tyrrell P., Perani D., Brooks D. J., Sager H., Jones T., Marsden C. D., Frackowiak R. S. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol. 1990 Dec;47(12):1290–1298. doi: 10.1001/archneur.1990.00530120034007. [DOI] [PubMed] [Google Scholar]
  25. Lundkvist C., Halldin C., Swahn C. G., Hall H., Karlsson P., Nakashima Y., Wang S., Milius R. A., Neumeyer J. L., Farde L. [O-methyl-11C]beta-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: preparation, autoradiography, metabolite studies, and positron emission tomography examinations. Nucl Med Biol. 1995 Oct;22(7):905–913. doi: 10.1016/0969-8051(95)00029-w. [DOI] [PubMed] [Google Scholar]
  26. Marek K. L., Seibyl J. P., Zoghbi S. S., Zea-Ponce Y., Baldwin R. M., Fussell B., Charney D. S., van Dyck C., Hoffer P. B., Innis R. P. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology. 1996 Jan;46(1):231–237. doi: 10.1212/wnl.46.1.231. [DOI] [PubMed] [Google Scholar]
  27. Marié R. M., Barré L., Rioux P., Allain P., Lechevalier B., Baron J. C. PET imaging of neocortical monoaminergic terminals in Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1995;9(1):55–71. doi: 10.1007/BF02252963. [DOI] [PubMed] [Google Scholar]
  28. Morrish P. K., Sawle G. V., Brooks D. J. Clinical and [18F] dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry. 1995 Dec;59(6):597–600. doi: 10.1136/jnnp.59.6.597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Neumeyer J. L., Tamagnan G., Wang S., Gao Y., Milius R. A., Kula N. S., Baldessarini R. J. N-substituted analogs of 2 beta-carbomethoxy-3 beta- (4'-iodophenyl)tropane (beta-CIT) with selective affinity to dopamine or serotonin transporters in rat forebrain. J Med Chem. 1996 Jan 19;39(2):543–548. doi: 10.1021/jm9505324. [DOI] [PubMed] [Google Scholar]
  30. Neumeyer J. L., Wang S., Gao Y., Milius R. A., Kula N. S., Campbell A., Baldessarini R. J., Zea-Ponce Y., Baldwin R. M., Innis R. B. N-omega-fluoroalkyl analogs of (1R)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)-tropane (beta-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem. 1994 May 27;37(11):1558–1561. doi: 10.1021/jm00037a004. [DOI] [PubMed] [Google Scholar]
  31. Rinne J. O., Laihinen A., Någren K., Ruottinen H., Ruotsalainen U., Rinne U. K. PET examination of the monoamine transporter with [11C]beta-CIT and [11C]beta-CFT in early Parkinson's disease. Synapse. 1995 Oct;21(2):97–103. doi: 10.1002/syn.890210202. [DOI] [PubMed] [Google Scholar]
  32. Seibyl J. P., Marek K. L., Quinlan D., Sheff K., Zoghbi S., Zea-Ponce Y., Baldwin R. M., Fussell B., Smith E. O., Charney D. S. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol. 1995 Oct;38(4):589–598. doi: 10.1002/ana.410380407. [DOI] [PubMed] [Google Scholar]
  33. Tedroff J., Aquilonius S. M., Hartvig P., Lundqvist H., Gee A. G., Uhlin J., Långström B. Monoamine re-uptake sites in the human brain evaluated in vivo by means of 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease. Acta Neurol Scand. 1988 Mar;77(3):192–201. doi: 10.1111/j.1600-0404.1988.tb05894.x. [DOI] [PubMed] [Google Scholar]
  34. Vermeulen R. J., Drukarch B., Verhoeff N. P., Goosen C., Sahadat M. C., Wolters E. C., van Royen E. A., Stoof J. C. No direct correlation between behaviorally active doses of the dopamine D2 agonist LY 171555 and displacement of [123I]IBZM as measured with SPECT in MPTP monkeys. Synapse. 1994 Jun;17(2):115–124. doi: 10.1002/syn.890170207. [DOI] [PubMed] [Google Scholar]
  35. Zigmond M. J., Abercrombie E. D., Berger T. W., Grace A. A., Stricker E. M. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 1990 Jul;13(7):290–296. doi: 10.1016/0166-2236(90)90112-n. [DOI] [PubMed] [Google Scholar]
  36. van Dyck C. H., Seibyl J. P., Malison R. T., Laruelle M., Wallace E., Zoghbi S. S., Zea-Ponce Y., Baldwin R. M., Charney D. S., Hoffer P. B. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT. J Nucl Med. 1995 Jul;36(7):1175–1181. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES